Autopsy report · NCT01277289

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

“due to the difficulty to enroll suitable patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 7 months after it had already started.
• Ran for about 3 years before it stopped.
• 51 participants enrolled.
• Results were posted on the registry 12 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Quince Therapeutics S.p.A.

Sponsor type

Industry

Conditions

Crohn's Disease

Interventions

Dexamethasone

Participants

51

Sites

8

Countries

Italy, Romania, Spain

Trials that died the same way

• Wellness Initiative at New York University
  “Due to inability to enroll patients” (91% match in meaning)
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (86% match in meaning)
• Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery
  “for difficulty to enroll patients in the study” (86% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (84% match in meaning)
• Ethanol Locks for the Treatment of Central Venous Line Infections
  “inability to enroll adequate number of patients” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.